Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients ; volume:38 ; number:12 ; day:16 ; month:8 ; year:2019 ; pages:3521-3528 ; date:12.2019
Clinical rheumatology ; 38, Heft 12 (16.8.2019), 3521-3528, 12.2019
- Creator
-
Presa, María
Pérez-Ruiz, Fernando
Oyagüez, Itziar
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-019-04739-3
- URN
-
urn:nbn:de:101:1-2020051022221901189889
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Presa, María
- Pérez-Ruiz, Fernando
- Oyagüez, Itziar
- SpringerLink (Online service)
Other Objects (12)
Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
Therapie mit Allopurinol : klin. Wirksamkeit verschiedener Allopurinol-Präparate
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Research progress on bariatric surgery for hyperuricemia
Die generalisierte Allopurinol-Überempfindlichkeitsreaktion
Allopurinol - zu oft und zu lange? : eine Querschnittserhebung zur Einnahme von Allopurinol
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
Sirolimus as a second-line treatment for Graves’ orbitopathy
Lesinurad plus Allopurinol bei Gicht
Gicht – Allopurinol-Behandlung und Sterblichkeitsrisiko
Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
Therapie mit Allopurinol : klin. Wirksamkeit verschiedener Allopurinol-Präparate
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Research progress on bariatric surgery for hyperuricemia
Die generalisierte Allopurinol-Überempfindlichkeitsreaktion
Allopurinol - zu oft und zu lange? : eine Querschnittserhebung zur Einnahme von Allopurinol
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
Sirolimus as a second-line treatment for Graves’ orbitopathy
Lesinurad plus Allopurinol bei Gicht
Gicht – Allopurinol-Behandlung und Sterblichkeitsrisiko
Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
Therapie mit Allopurinol : klin. Wirksamkeit verschiedener Allopurinol-Präparate
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Research progress on bariatric surgery for hyperuricemia
Die generalisierte Allopurinol-Überempfindlichkeitsreaktion
Allopurinol - zu oft und zu lange? : eine Querschnittserhebung zur Einnahme von Allopurinol
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
Sirolimus as a second-line treatment for Graves’ orbitopathy
Lesinurad plus Allopurinol bei Gicht